{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T04:01:50Z","timestamp":1746849710586,"version":"3.40.5"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,8]]},"DOI":"10.7759\/cureus.83763","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T06:43:07Z","timestamp":1746772987000},"source":"Crossref","is-referenced-by-count":0,"title":["Epidermal Growth Factor Receptor (EGFR) Downregulation by Cetuximab in Salivary Duct Carcinoma: A Case Report"],"prefix":"10.7759","author":[{"given":"Hikari","family":"Saito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takumi","family":"Kumai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michihisa","family":"Kono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenzo","family":"Ohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miki","family":"Takahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/hed.27034","article-title":"The implicated clinical factors for outcomes in 304 patients with salivary duct carcinoma: Multi-institutional retrospective analysis in Japan","volume":"44","author":"Kusafuka K","year":"2022","unstructured":"Kusafuka K, Sato Y, Nakatani E, et al.. The implicated clinical factors for outcomes in 304 patients with salivary duct carcinoma: Multi-institutional retrospective analysis in Japan. Head Neck. 2022, 44:1430-41. 10.1002\/hed.27034","journal-title":"Head Neck"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00545","article-title":"Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma","volume":"37","author":"Takahashi H","year":"2019","unstructured":"Takahashi H, Tada Y, Saotome T, et al.. Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma. J Clin Oncol. 2019, 37:125-34. 10.1200\/JCO.18.00545","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32795","article-title":"Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients","volume":"146","author":"van Boxtel W","year":"2020","unstructured":"van Boxtel W, Verhaegh GW, van Engen-van Grunsven IA, et al.. Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients. Int J Cancer. 2020, 146:3196-206. 10.1002\/ijc.32795","journal-title":"Int J Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.anl.2024.05.007","article-title":"Differential expression of epidermal growth factor receptor in various pathological types of salivary gland cancers","volume":"51","author":"Fujiwara H","year":"2024","unstructured":"Fujiwara H, Kodama Y, Shimoda H, Teshima M, Shinomiya H, Nibu KI. Differential expression of epidermal growth factor receptor in various pathological types of salivary gland cancers. Auris Nasus Larynx. 2024, 51:755-60. 10.1016\/j.anl.2024.05.007","journal-title":"Auris Nasus Larynx"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/hed.26529","article-title":"Therapeutic implications of immune-profiling and EGFR expression in salivary gland carcinoma","volume":"43","author":"Guazzo E","year":"2021","unstructured":"Guazzo E, Cooper C, Wilkinson L, et al.. Therapeutic implications of immune-profiling and EGFR expression in salivary gland carcinoma. Head Neck. 2021, 43:768-77. 10.1002\/hed.26529","journal-title":"Head Neck"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31353","article-title":"A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands","volume":"143","author":"Boon E","year":"2018","unstructured":"Boon E, Bel M, van Boxtel W, et al.. A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands. Int J Cancer. 2018, 143:758-66. 10.1002\/ijc.31353","journal-title":"Int J Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/hed.23906","article-title":"Assessment of the change in cetuximab-induced antibody-dependent cellular cytotoxicity activity of natural killer cells by steroid","volume":"38","author":"Kumai T","year":"2016","unstructured":"Kumai T, Oikawa K, Aoki N, Kimura S, Harabuchi Y, Kobayashi H. Assessment of the change in cetuximab-induced antibody-dependent cellular cytotoxicity activity of natural killer cells by steroid. Head Neck. 2016, 38:410-6. 10.1002\/hed.23906","journal-title":"Head Neck"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1159\/000534516","article-title":"Efficacy of cetuximab combined with paclitaxel in patients with recurrent salivary gland carcinoma: a retrospective observational study","volume":"86","author":"Sato R","year":"2024","unstructured":"Sato R, Yuasa R, Kumai T, et al.. Efficacy of cetuximab combined with paclitaxel in patients with recurrent salivary gland carcinoma: a retrospective observational study. ORL J Otorhinolaryngol Relat Spec. 2024, 86:41-9. 10.1159\/000534516","journal-title":"ORL J Otorhinolaryngol Relat Spec"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.anl.2023.09.006","article-title":"Near-infrared photoimmunotherapy for salivary duct carcinoma","volume":"51","author":"Makino T","year":"2024","unstructured":"Makino T, Sato Y, Uraguchi K, Naoi Y, Fukuda Y, Ando M. Near-infrared photoimmunotherapy for salivary duct carcinoma. Auris Nasus Larynx. 2024, 51:323-7. 10.1016\/j.anl.2023.09.006","journal-title":"Auris Nasus Larynx"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00106-004-1204-z","article-title":"Salivary duct carcinoma of the submandibular gland [Article in German]","volume":"53","author":"Jaehne M","year":"2005","unstructured":"Jaehne M, Dippel A, Sagowski C. Salivary duct carcinoma of the submandibular gland [Article in German]. HNO. 2005, 53:940-4. 10.1007\/s00106-004-1204-z","journal-title":"HNO"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1017\/S0022215114002965","article-title":"Is there a role of adjuvant treatment for salivary duct carcinoma?","volume":"129","author":"Nakashima T","year":"2015","unstructured":"Nakashima T, Yasumatsu R, Toh S, Hashimoto K, Shinoto M, Nakamura K, Komune S. Is there a role of adjuvant treatment for salivary duct carcinoma?. J Laryngol Otol. 2015, 129:S98-101. 10.1017\/S0022215114002965","journal-title":"J Laryngol Otol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2015.3930","article-title":"A 20-year review of 75 cases of salivary duct carcinoma","volume":"142","author":"Gilbert MR","year":"2016","unstructured":"Gilbert MR, Sharma A, Schmitt NC, Johnson JT, Ferris RL, Duvvuri U, Kim S. A 20-year review of 75 cases of salivary duct carcinoma. JAMA Otolaryngol Head Neck Surg. 2016, 142:489-95. 10.1001\/jamaoto.2015.3930","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2025.105736","article-title":"Re-evaluation of histopathological factors for the outcome of salivary duct carcinoma patients: a multi-institutional retrospective study of 240 cases in a Japanese cohort","volume":"155","author":"Kusafuka K","year":"2025","unstructured":"Kusafuka K, Nakatani E, Baba S, et al.. Re-evaluation of histopathological factors for the outcome of salivary duct carcinoma patients: a multi-institutional retrospective study of 240 cases in a Japanese cohort. Hum Pathol. 2025, 155:105736. 10.1016\/j.humpath.2025.105736","journal-title":"Hum Pathol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12889-0","article-title":"A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma - the DUCT study protocol","volume":"24","author":"Weijers JA","year":"2024","unstructured":"Weijers JA, Verhaegh GW, Lassche G, et al.. A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma - the DUCT study protocol. BMC Cancer. 2024, 24:1174. 10.1186\/s12885-024-12889-0","journal-title":"BMC Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221119538","article-title":"Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma","volume":"14","author":"Kawakita D","year":"2022","unstructured":"Kawakita D, Nagao T, Takahashi H, et al.. Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma. Ther Adv Med Oncol. 2022, 14:17588359221119538. 10.1177\/17588359221119538","journal-title":"Ther Adv Med Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2017.1226","article-title":"Salivary duct carcinoma treated with cetuximab-based targeted therapy: a case report","volume":"6","author":"Kawahara K","year":"2017","unstructured":"Kawahara K, Hiraki A, Yoshida R, et al.. Salivary duct carcinoma treated with cetuximab-based targeted therapy: a case report. Mol Clin Oncol. 2017, 6:886-92. 10.3892\/mco.2017.1226","journal-title":"Mol Clin Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19812","article-title":"Biomarker immunoprofile in salivary duct carcinomas: clinicopathological and prognostic implications with evaluation of the revised classification","volume":"8","author":"Takase S","year":"2017","unstructured":"Takase S, Kano S, Tada Y, et al.. Biomarker immunoprofile in salivary duct carcinomas: clinicopathological and prognostic implications with evaluation of the revised classification. Oncotarget. 2017, 8:59023-35. 10.18632\/oncotarget.19812","journal-title":"Oncotarget"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/path.6230","article-title":"Decreased HER2 expression in endometrial cancer following anti-HER2 therapy","volume":"262","author":"Chui MH","year":"2024","unstructured":"Chui MH, Brown DN, Da Cruz Paula A, et al.. Decreased HER2 expression in endometrial cancer following anti-HER2 therapy. J Pathol. 2024, 262:129-36. 10.1002\/path.6230","journal-title":"J Pathol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14225698","article-title":"Approaches to the management of metastatic adenoid cystic carcinoma","volume":"14","author":"Lee RH","year":"2022","unstructured":"Lee RH, Wai KC, Chan JW, Ha PK, Kang H. Approaches to the management of metastatic adenoid cystic carcinoma. Cancers (Basel). 2022, 14:5698. 10.3390\/cancers14225698","journal-title":"Cancers (Basel)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34972","article-title":"Comprehensive genomic profiling of salivary gland carcinoma: analysis of the Center for Cancer Genomics and Advanced Therapeutics database in Japan","volume":"155","author":"Iwaki S","year":"2024","unstructured":"Iwaki S, Kawakita D, Nagao T, et al.. Comprehensive genomic profiling of salivary gland carcinoma: analysis of the Center for Cancer Genomics and Advanced Therapeutics database in Japan. Int J Cancer. 2024, 155:871-82. 10.1002\/ijc.34972","journal-title":"Int J Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/365033-epidermal-growth-factor-receptor-egfr-downregulation-by-cetuximab-in-salivary-duct-carcinoma-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T06:43:08Z","timestamp":1746772988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/365033-epidermal-growth-factor-receptor-egfr-downregulation-by-cetuximab-in-salivary-duct-carcinoma-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.83763","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,8]]}}}